Eleftha 440mg injection is a prescription medication, manufactured by Intas pharmaceuticals , containing trastuzumab (440mg) ,used for treating HER2-positive breast and stomach cancers. As a targeted immunotherapy, it works by binding to HER2 proteins on cancer cells, inhibiting their growth and promoting tumor death . it is administered via intravenous infusion in a hospital setting.
Targeted therapy is a precision cancer treatment that uses drugs to identify and attack specific cancer cells while sparing healthy tissue. Often inhibiting cancer growth signaling inducing cell death, or cutting off blood supply. It acts like a “guided missile’’ focusing on genetic mutations or biomarkers.
WHAT IS ELEFTHA 440?
Eleeftha 440 injection is a prescription cancer medication containing trastuzumab ,a targated therapy used to treat HER2-positive breast and stomach cancers. It act as a monoclonal antibody that inhibit the growth of cancer cells by targeting HER2 proteins.
Key classification:
- · Active ingredient: Trastuzumab
- Drug class: monoclonal antibody (IgG1)
- Indications : HER2-positive metastatic breast cancer and metastatic gastric cancer.
- Mechanism: binds selectively to the extracelluar domain of HER2 receptor, stopping cancer cell growth.
- Administration: intravenous (IV) injection/infusion ,typically administered by a medical professional.
- Requirement: requires HER_2 positive testing: ineffective on HER_2 negative cancer cells.
WHAT ARE THE MEDICAL USES OF ELEFTHA 440 INJECTION?
Medical uses of ELEFTHA 440 injection are:
1. Treatment of HER_2 positive breast cancer
Eleftha 440 injection is a monoclonal antibody containing Trastuzumab , used to treat HER-2 positive breast cancer . it works by targeting the HER 2 protein, inhibiting tumor growth . it is given intravenously, usually in combination with chemotherapy or alone, often a three weekly scheduled . it targets the HER2 receptors on cancer cells ,reducing proliferation and initiating programed cell death. Regular heart functioning monitoring is required during treatment. It is use with caution ,or avoid in individuals with severe breathing issues or existing heart disease.
2. Treatment of HER-2 positive gastric cancer
eleftha 440 mg injection is a monoclonal antibody therapy used to treat HER-2 positive metastatic gastric or gastroesopahageal junction. It inhibits HER2 protein signaling, showing cancer cell growth . it is administered via intravenous infusion by a healthcare professional, commonly paired with chemotherapy for advanced cases. It is used for patients whose tumor cells overexpress the HER2 protein which must be confirmed by testing prior to treatment. It targets the HER2 receptors to stop the proliferation of cancer cells and mark them for destruction by the immune system. It is crucial to monitor heart function during treatment ,as it can cause heart-related issues.
3. Used alone or in combination with COMPREHENSIVE GUIDE TO CHEMOTHERAPY AND CANCER CARE
Eleftha 440 mg injection containing trastuzmab , is a HER2-positive breast and gastric cancers. It can be administered alone (monotherapy) or in combination with chemotherapy to slow disease progression and improve survival, typically given as an intravenous infusion by an oncologist. It is used after one or more chemotherapy regimens for metastatic breast cancer ,also often used with paclitaxel or docetaxel for metastatic breast cancer and with capacitance or 5- fluorouracil and cisplatin for metastatic gastric cancer. It specifically binds to HER2 receptors on cancer cells, blocking growth signals and promoting cell destruction.
WHAT ARE THE BENEFIS OF ELEFTHA 440 INJECTION?
Benefits of Eleftha 440 injection are:
1. Targets cancer cells specifically (HER2-positive)
Eleftha 440 mg injection is a targeted therapy contains trastuzumab, which specifically targets and binds to HER2 proteins found in high amounts on certain cancer cells. It works by attaching itself to HER2 protein, which signals the body’s immune system to kill the cancer cells, or by blocking the HER2 receptors ,thus slowing or stopping cancer growth.
2. Helps slow or stop tumor growth
Eleftha 440 mg injection ,which contains the active ingredient trastuzumab, is a targeted therapy to help slow or stop the growth of specific types of cancer. It works primarily by targeting HER2 –positive cancer cells. As a monoclonal antibody, it binds to HER2 protein, which is found in higher amounts on the surface of some cancer cells. This action inhibit the HER2 protein from signaling the cancer cells to grow and divide, effectively slowing or stopping tumor progression. It also assist the immune system in destroying these cells.
3. Improves treatment outcomes when combined with chemotherapy
Eleftha 440 mg is designed to improve treatment outcomes when combined with chemotherapy, particularly in HER2-pateints. It is a targated therapy that act as a humanized monoclonal antibody to bind with HER2 receptors , inhibiting tumor growth and promoting the destruction of cancer cells. Combined with chemotherapy agents, it improves disease –free survival and overall survival rates. It is often utilized to reduce the risk of cancer recurrence after surgery in early-stage HER2-positive breast cancer. Studies indicate that Eleftha when combined with chemotherapy can reduce tumor size and enhance treatment success in both adjuvant and metastatic settings.
WHAT ARE THE SIDE EFFECTS OF ELEFTHA 440 INJECTION?
Side effects of Eleftha 440 injection are:
1. Fever and chills
Fever and chills are very common side effect of Eleftha 440 injection , particularly during or shortly after infusion . These are often part of ‘’infusion –related reactions’’ that occur as the body adjust to medication. Some of the common symptoms after infusing Eleftha 440 injection are shivering, nausea, vomiting headache, rash and fatigue. Doctors often use premedication such as paracetamol to help reduce these symptoms.
2. Diarrhea
Diarrhea is a common side effect of Elftha 440 injection, which is a brand of trastuzumab used in cancer treatment .it occurs as a part of the body’s response to the medication along with nausea, vomiting and abdominal pain. In some studies ,diarrhea was reported in approximately 9.8% of patients. While common, severe or persistent diarrhea should be reported to a doctor immediately .
Conclusion
Eleftha 440 m is a targeted therapy containing Trastuzumab , used to treat HER2- positive breast cancer and metastatic gastric cancer by inhibiting the overexpression of the HER2 protein. It is generally considered a effective , high-quality and cost-effective alternative to brand –name trastuzumab, often used with other treatment have not shown significant improvement.
FREQUENTLY ASKED QUESTIONS (FAQs)
QUESTION: WHAT IS HER2- Positive BREAST CANCER?
HER2- positive breast cancer is an aggressive form of cancer where cancer cells have high levels of the human epidermal growth factor receptor 2(HER2) protein, promoting rapid growth. Affecting 15-20% of breast cancer patients, it is treated with targeted therapies like trastuzumab (Herceptin) ,chemotherapy and surgery ,which have greatly improved survival.
QUESTION: HOW LONG DOES TREATMENT WITH ELEFTHA 440 LAST?
Treatment with ELEFTHA 440 for early breast cancer generally last for 1 year . for advanced or metastatic breast/stomach cancer ,treatment continues for as long as it is effective and tolerated, often determined by disease progression.
QUESTION: IS CHEMOTHERAPY A TARGETED THERAPY?
Chemotherapy is not considered a targeted therapy . while both are systematic cancer treatments, chemotherapy acts broadly by killing all rapidly dividing cells, including healthy ones , leading to severe side effects . targeted therapy is a new precision medicine that specifically interfere with molecules supporting cancer growth.
REFRENCES
1.https://www.apothecare.in/products/eleftha-440mg-injection
2.https://m.indiamart.com/proddetail/eleftha-440-mg-injection-21654777512.html.
3.https://www.medkart.in/order-medicine/eleftha-440mg-injection?srsltid=AfmBOorBnfKzKDSn82xNVhyX8pnMmbZ3uKrTs4Uzmn10BYRXJAPql6-R
